(3) From the experience of using Darbe and Epo, in cancer patients, taking into consideration the duration of clinical benefit (DCB) that is 2–7 days in Epo and 7–21 days in Darbe, one study showed, after accounting for DCB, that the average weekly cost of darbepoetin alfa was significantly lower than that of epoetin alfa ($619 vs. $940; p < 0.001) [35]. Here, EPO is linked to cancer.